Ipragliflozin

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bioavailability of Ipragliflozin

Conditions

Bioavailability of Ipragliflozin, Healthy Subjects

Trial Timeline

Jun 1, 2011 → Jul 1, 2011

NCT ID

NCT01611428

About Ipragliflozin

Ipragliflozin is a phase 1 stage product being developed by Astellas Pharma for Bioavailability of Ipragliflozin. The current trial status is completed. This product is registered under clinical trial identifier NCT01611428. Target conditions include Bioavailability of Ipragliflozin, Healthy Subjects.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02291874	Approved	Completed	Oct 8, 2014	Jul 7, 2016	Type 2 Diabetes Mellitus
NCT02479399	Pre-clinical	Completed	Jul 17, 2014	Oct 16, 2018	Type 2 Diabetes
NCT01672762	Phase 3	Completed	May 25, 2012	Apr 13, 2013	Type 2 Diabetes Mellitus
NCT01611428	Phase 1	Completed	Jun 1, 2011	Jul 1, 2011	Bioavailability of Ipragliflozin
NCT01054092	Phase 3	Completed	Jan 14, 2010	Jul 22, 2011	Type 2 Diabetes Mellitus

Competing Products

20 competing products in Bioavailability of Ipragliflozin

See all competitors

Product	Company	Stage	Hype Score
solifenacin succinate suspension + solifenacin succinate tablet	Astellas Pharma	Phase 1	33
ASP015K	Astellas Pharma	Phase 1	33
ASP015K	Astellas Pharma	Phase 1	33
Hetrombopag	Jiangsu Hengrui Medicine	Phase 1	33
ABT-450/r/ABT-267	AbbVie	Phase 1	33
ABT-333	AbbVie	Phase 1	33
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2	AstraZeneca	Phase 1	33
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orally	AstraZeneca	Phase 1	33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single dose	AstraZeneca	Phase 1	33
selumetinib 75mg single dose	AstraZeneca	Phase 1	33
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube	AstraZeneca	Phase 1	33
AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423	AstraZeneca	Phase 1	33
Fostamatinib + Fostamatinib + Fostamatinib + Fostamatinib	AstraZeneca	Phase 1	33
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg	AstraZeneca	Phase 1	33
D1400147 + D14000136 + D14000137 + Epanova®	AstraZeneca	Phase 1	33
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water	AstraZeneca	Phase 1	33
NKTR-118 + Ketoconazole	AstraZeneca	Phase 1	33
TEPEZZA + EDP	Amgen	Phase 1	32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir	Pfizer	Phase 1	32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332	Pfizer	Phase 1	32

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved